In this study, we investigate the veliparib‑induced toxicity in cancer patients. Databases were searched for RCTs treated with veliparib. We found veliparib could increase the risk of hematologic and gastrointestinal toxicities. Anemia, neutropenia, thrombocytopenia, and nausea were the most common toxicities. Patients diagnosed with gastrointestinal tumors tend to have a higher risk of high-grade neutropenia; patients in the first-line setting tend to have a higher risk of high-grade anemia and neutropenia than those in the ≥ second line setting. Patients receiving higher dosage of veliparib tend to have a higher risk of all-grade anemia. Veliparib could also increase the risk of insomnia, myalgia, pneumonia, dyspnea, hyponatremia, and fatigue.
Keyphrases
- end stage renal disease
- high grade
- chronic kidney disease
- newly diagnosed
- ejection fraction
- oxidative stress
- high glucose
- peritoneal dialysis
- low grade
- heart failure
- diabetic rats
- chemotherapy induced
- drug induced
- intensive care unit
- machine learning
- patient reported
- palliative care
- depressive symptoms
- acute respiratory distress syndrome